A phase 1 study of SJG-136 in patients with Advanced Leukemia.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs SG 2000 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Jan 2013 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
- 07 Jun 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.